Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction

References

• Musicki B, Bella AJ, Bivalacqua TJ, et al. Basic science evidence for the link between erectile dysfunction and cardiometabolic dysfunction. J Sex Med. 2015;12:2233–2255.
   PubMed Web of Science ®Google Scholar
• Pontin D, Porter T, McDonagh R. Investigating the effect of erectile dysfunction on the lives of men: a qualitative research study. J Clin Nurs. 2002;11:264–272.
   PubMed Web of Science ®Google Scholar
• McCabe M, Matic H. Severity of ED: relationship to treatment-seeking and satisfaction with treatment using PDE5 inhibitors. J Sex Med. 2007;4:145–151.
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Kaufman J, Magee M, et al. Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction. BMC Urol. 2010;10:18.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Wei JT, Althof SE, et al. BPH registry and patient survey steering committee. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology. 2009;73:562–566.
   PubMed Web of Science ®Google Scholar
• Ozayar A, Zumrutbas AE, Yaman O. The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH. Int Urol Nephrol. 2008;40:933–939.
   PubMed Web of Science ®Google Scholar
• Seftel AD, De la Rosette J, Birt J, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67:32–45.
   PubMed Web of Science ®Google Scholar
• Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male. 2015;18:112–117.
   PubMed Web of Science ®Google Scholar
• Park SG, Yeo JK, Cho DY, et al. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2017;17:1–5.
   Web of Science ®Google Scholar
• Asiedu B, Anang Y, Nyarko A, et al. The role of sex steroid hormones in benign prostatic hyperplasia. Aging Male. 2017;20:17–22.
   PubMed Web of Science ®Google Scholar
• Allen S, Aghajanyan I. Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology. Aging Male. 2017;20:28–32.
   PubMed Web of Science ®Google Scholar
• Ren H, Li X, Cheng G, et al. The effects of ROS in prostatic stromal cells under hypoxic environment. Aging Male. 2015;18:84–88.
   PubMed Web of Science ®Google Scholar
• Ferreira FT, Daltoé L, Succi G, et al. Relation between glycemic levels and low tract urinary symptoms in elderly. Aging Male. 2015;18:34–37.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee JY, O'Neill EA, et al. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male. 2013;16:169–172.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, O'Neill E, Lowe R, et al. Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS). Aging Male. 2013;16:48–51.
   PubMed Web of Science ®Google Scholar
• Aktas BK, Gokkaya CS, Bulut S, et al. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients. Aging Male. 2011;14:48–52.
   PubMed Web of Science ®Google Scholar
• Amano T, Earle C, Imao T, et al. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. Aging Male. 2017;22:1–6.
   Web of Science ®Google Scholar
• Ko WJ, Han HH, Ham WS, et al. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–88.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–181.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Kaufman JM. The effect of androgen supplementation therapy on the prostate. Aging Male. 2003;6:166–174.
   PubMedGoogle Scholar
• Haider KS, Haider A, Doros G, et al. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol. 2018;199:257–265.
   PubMed Web of Science ®Google Scholar
• Kosilov K, Kuzina I, Kuznetsov V, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male. 2017;7:1–9.
   Web of Science ®Google Scholar
• Henningsohn L, Kilany S, Svensson M, et al. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study. Aging Male. 2017;20:266–276.
   PubMed Web of Science ®Google Scholar
• Rosen R, Carson C, Giuliano F. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824–837.
   PubMed Web of Science ®Google Scholar
• Marshall LM, Holton KF, Parsons JK, Osteoporotic Fractures in Men (MrOS) Study Group, et al. Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men. Prostate Cancer Prostatic Dis. 2014;17:265–272.
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978–2984.
   PubMed Web of Science ®Google Scholar
• Shiyi C, Xiaoxu Y, Yunxia W, et al. Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLoS One. 2013;8:e60443.
   PubMed Web of Science ®Google Scholar
• Shaarawy M, Mahmoud KZ. Endocrine profile and semen characteristics in male smokers. Fertil Steril. 1982;38:255–257.
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149–2155.
   PubMed Web of Science ®Google Scholar
• Huang YC, Chin CC, Chen CS, et al. Chronic cigarette smoking impairs erectile function through increased oxidative stress and apoptosis, decreased nNOS, endothelial and smooth muscle contents in a rat model. PLoS One. 2015;10:e0140728.
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, Van de Borne PJ, Hausberg M, et al. Cigarette smoking increases sympathetic outflow in humans. Circulation. 1998;98:528–534.
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Crespo CJ, Weber JR, et al. Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health and Nutrition Examination Survey. BJU Int. 2005;96:77–82.
   PubMed Web of Science ®Google Scholar
• Maserejian NN, Kupelian V, Miyasato G, et al. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol. 2012;188:490–495.
   PubMed Web of Science ®Google Scholar
• Knuutinen A, Kokkonen N, Risteli J, et al. Smoking affects collagen synthesis and extracellular matrix turnover in human skin. Br J Dermatol. 2002;146:588–594.
   PubMed Web of Science ®Google Scholar
• Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139:161–168.
   PubMed Web of Science ®Google Scholar
• Kalter-Leibovici O, Wainstein J, Ziv A, et al. Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care. 2005;28:1739–1744.
   PubMed Web of Science ®Google Scholar
• Martin SA, Atlantis E, Lange K, et al. Predictors of sexual dysfunction incidence and remission in men. J Sex Med. 2014;11:1136–1147.
   PubMed Web of Science ®Google Scholar
• Chew KK, Bremner A, Stuckey B, et al. Alcohol consumption and male erectile dysfunction: an unfounded reputation for risk? J Sex Med. 2009;6:1386–1394.
   PubMedGoogle Scholar
• Cheng JY, Ng EM, Chen RY, et al. Alcohol consumption and erectile dysfunction: meta-analysis of population-based studies. Int J Impot Res. 2007;19:343–352.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol. 2009;182:1463–1468.
   PubMed Web of Science ®Google Scholar
• Wong SY, Woo J, Leung JC, et al. Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men: a prospective study. Aging Male. 2010;13:113–119.
   PubMed Web of Science ®Google Scholar
• Kristal AR, Arnold KB, Schenk JM, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;167:925–934.
   PubMed Web of Science ®Google Scholar
• Eggleton MG. The diuretic action of alcohol in man. J Physiol (Lond). 1942;101:172–191.
   Google Scholar
• Van de Borne P, Mark AL, Montano N, et al. Effects of alcohol on sympathetic activity, hemodynamics, and chemoreflex sensitivity. Hypertension. 1997;29:1278–1283.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60:458–465.
   PubMed Web of Science ®Google Scholar
• Ahn TY, Park JK, Lee SW, et al. Prevalence and risk factors for erectile dysfunction in Korean men: results of an epidemiological study. J Sex Med. 2007;4:1269–1276.
   PubMed Web of Science ®Google Scholar
• Shiri R, Koskimäki J, Tammela TL, et al. Bidirectional relationship between depression and erectile dysfunction. J Urol. 2007;177:669–673.
   PubMed Web of Science ®Google Scholar
• Maes M, Yirmyia R, Noraberg J, et al. The inflammatory & neurodegenerative hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009;24:27–53.
   PubMed Web of Science ®Google Scholar
• Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One. 2014;9:e85588.
   PubMedGoogle Scholar
• Kim SW, Paick JS, Park DW, et al. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology. 2001;58:441–445.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996–3002.
   PubMed Web of Science ®Google Scholar
• Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension. 1997;29:8–14.
   PubMed Web of Science ®Google Scholar
• Newman HF, Marcus H. Erectile dysfunction in diabetes and hypertension. Urology. 1985;26:135–137.
   PubMed Web of Science ®Google Scholar
• Javaroni V, Neves MF. Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. Int J Hypertens. 2012;2012:627278.
   PubMedGoogle Scholar
• Ito H, Yoshiyasu T, Yamaguchi O, et al. Male lower urinary tract symptoms: hypertension as a risk factor for storage symptoms, but not voiding symptoms. Low Urin Tract Symptoms. 2012;4:68–72.
   PubMed Web of Science ®Google Scholar
• Hwang EC, Kim SO, Nam DH, et al. Men with hypertension are more likely to have severe lower urinary tract symptoms and large prostate volume. Low Urin Tract Symptoms. 2015;7:32–36.
   PubMed Web of Science ®Google Scholar
• DeLay KJ, Haney N, Hellstrom WJ. Modifying risk factors in the management of erectile dysfunction: a review. World J Mens Health. 2016;34:89–100.
   PubMedGoogle Scholar
• Swyer G. Cholesterol content of normal and enlarged prostates. Cancer Res. 1942;2:372–375.
   Google Scholar
• Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370:89–93.
   PubMed Web of Science ®Google Scholar
• Corona G, Vignozzi L, Rastrelli G, et al. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014:329456.
   PubMed Web of Science ®Google Scholar
• Bourke JB, Griffin JP. Diabetes mellitus in patients with benign prostatic hyperplasia. BMJ. 1968;4:492–493.
   PubMed Web of Science ®Google Scholar
• Lotti F, Corona G, Vignozzi L, et al. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl. 2014;16:295–304.
   PubMed Web of Science ®Google Scholar
• Lotti F, Corona G, Colpi GM, et al. Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. J Endocrinol Investig. 2011;34:336–342.
   PubMed Web of Science ®Google Scholar
• La Vignera S, Condorelli RA, Russo GI, et al. Endocrine control of benign prostatic hyperplasia. Andrology. 2016;4:404–411.
   PubMed Web of Science ®Google Scholar
• Marmorston J, Lombardo LJ Jr, Myers SM, et al. Urinary excretion of estrone, estradiol and estriol by patients with prostatic cancer and benign prostate hypertrophy. J Urol. 1965;93:287–295.
   PubMed Web of Science ®Google Scholar
• Kullmann FA, Birder LA, Andersson KE. Translational research and functional changes in voiding function in older adults. Clin Geriatr Med. 2015;31:535–548.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Kato R, Chancellor MB, et al. Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther. 2010;10:1305–1314.
   PubMed Web of Science ®Google Scholar
• Bechis SK, Otsetov AG, Ge R, et al. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014;192:16–23.
   PubMed Web of Science ®Google Scholar
• Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256–1261.
   PubMed Web of Science ®Google Scholar
• Parsons JK. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. Curr Opin Urol. 2011;21:1–4.
   PubMed Web of Science ®Google Scholar
• Park HJ, Won J, Sorsaburu S, et al. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health. 2013;31:193–207.
   PubMedGoogle Scholar
• La Vignera S, Condorelli R, Vicari E, et al. Physical activity and erectile dysfunction in middle-aged men. J Androl. 2012;33:154–161.
   PubMed Web of Science ®Google Scholar